Reviewing Pulse Biosciences (NASDAQ:PLSE) & AngioDynamics (NASDAQ:ANGO)
by Tristan Rich · The Markets DailyAngioDynamics (NASDAQ:ANGO – Get Free Report) and Pulse Biosciences (NASDAQ:PLSE – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares AngioDynamics and Pulse Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AngioDynamics | $320.17 million | 1.97 | -$36.74 million | ($0.87) | -17.55 |
| Pulse Biosciences | $350,000.00 | 10,502.12 | -$72.78 million | ($1.18) | -45.01 |
AngioDynamics has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 6.0% of AngioDynamics shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
AngioDynamics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
Profitability
This table compares AngioDynamics and Pulse Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AngioDynamics | -11.48% | -5.73% | -3.77% |
| Pulse Biosciences | -6,755.78% | -94.42% | -79.96% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for AngioDynamics and Pulse Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AngioDynamics | 2 | 0 | 2 | 1 | 2.40 |
| Pulse Biosciences | 1 | 0 | 4 | 1 | 2.83 |
AngioDynamics currently has a consensus target price of $19.50, indicating a potential upside of 27.70%. Pulse Biosciences has a consensus target price of $45.25, indicating a potential downside of 14.80%. Given AngioDynamics’ higher probable upside, analysts clearly believe AngioDynamics is more favorable than Pulse Biosciences.
Summary
AngioDynamics beats Pulse Biosciences on 9 of the 14 factors compared between the two stocks.
About AngioDynamics
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.